Nivolumab plus Ipilimumab in advanced melanoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • CTLA-4 Antigen
  • Melanoma
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms

abstract

  • Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; ClinicalTrials.gov number, NCT01024231.).

publication date

  • July 23, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1302369

PubMed ID

  • 23724867

Additional Document Info

start page

  • 122

end page

  • 33

volume

  • 369

number

  • 2